Catalyst
Slingshot members are tracking this event:
Phase 1/2 data of CAP-1002 HOPE-Duchenne trial for DMD
- Source Link:
- http://www.irdirect.net/pr/release/id/1602810
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CAPR |
|
|
||||
Additional Information
The HOPE-Duchenne clinical trial is open for enrollment. The Company expects to report topline data from HOPE-Duchenne by the first quarter of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2017
Occurred Source:
https://seekingalpha.com/filings/pdf/12011025.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2 Data, Cap-1002, Hope-duchenne Trial, Dmd, Duchenne Muscular Dystrophy, Q1 2017
